混合性肝癌术后个案分析并文献复习
A Case Analysis and Literature Review of Combined Hepatocellular-Cholangiocarcinoma after Operation
DOI: 10.12677/ACM.2023.131120, PDF,   
作者: 王翰林：青岛大学医学部，山东 青岛；郭卫东*：青岛大学附属医院肝胆外科，山东 青岛
关键词: 胆管细胞癌；混合性肝癌；肝切除术；全身治疗；ICC； cHCC-CCA； Hepatic Resection； Systemic Treatment
摘要: 目的：探讨目前混合性肝癌的诊疗策略及进展。方法：回顾性分析2020年11月青岛大学附属医院肝胆外科收治1例混合性肝癌患者的临床特征、实验室检查指标、诊疗经过及治疗转归，并结合相关文献复习展开讨论。结果：患者女，53岁，因原发性肝恶性肿瘤入院，完整肿瘤切除后早期复发(6月)，经全身治疗获得二次手术机会，术后随访6月无复发。结论：混合性肝癌由于其肿瘤特性以及其低发病率，目前暂无明确的诊治指导方案，个体化的分阶段治疗可能使患者获益。
Abstract: Objective: To explore the diagnosis and treatment strategy and progress of mixed liver cancer. Methods: The clinical characteristics, laboratory examination indexes, diagnosis and treatment process and treatment outcome of a patient with mixed liver cancer admitted to the Department of Hepatobiliary Surgery of the Affiliated Hospital of Qingdao University in November 2020 were ana-lyzed retrospectively, and the related literature was reviewed for discussion. Results: A 53-year-old female patient was admitted to the hospital for primary hepatic malignant tumor. The complete tumor recurred early after resection (6 months). After systemic treatment, she received a second operation opportunity. There was no recurrence after 6 months of follow-up. Conclusion: Because of its tumor characteristics and low incidence rate, there is no clear diagnosis and treatment guidance plan for mixed liver cancer at present. Individualized phased treatment may benefit patients.
文章引用：王翰林, 郭卫东. 混合性肝癌术后个案分析并文献复习[J]. 临床医学进展, 2023, 13(1): 824-830. https://doi.org/10.12677/ACM.2023.131120

参考文献

[1] Beaufrere, A., Calderaro, J. and Paradis, V. (2021) Combined Hepatocellular-Cholangiocarcinoma: An Update. Journal of Hepatology, 74, 1212-1224. [Google Scholar] [CrossRef] [PubMed]
[2] Morizono, S., Fukutomi, M., Yo-kota, M., et al. (2002) A Case of Combined Liver Cell and Bile Duct Carcinoma Detected 6 Years after Interferon Ther-apy for Chronic Hepatitis C, in Spite of Showing Complete Response. Nihon Shokakibyo Gakkai Zasshi, 99, 505-510.
[3] Goodman, Z.D., Ishak, K.G., Langloss, J.M., et al. (1985) Combined Hepatocellular-Cholangiocarcinoma. A Histologic and Immunohistochemical Study. Cancer, 55, 124-135. [Google Scholar] [CrossRef] 
[4] Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histo-pathology, 76, 182-188. [Google Scholar] [CrossRef] [PubMed]
[5] Fong, Y., Sun, R.L., Jarnagin, W., et al. (1999) An Analysis of 412 Cases of Hepatocellular Carcinoma at a Western Center. Annals of Surgery, 229, 790-799. [Google Scholar] [CrossRef] [PubMed]
[6] Zhou, Y.M., Zhang, X.F., Wu, L.P., et al. (2014) Risk Factors for Combined Hepatocellular-Cholangiocarcinoma: A Hospital-Based Case-Control Study. World Journal of Gastroenterology, 20, 12615-12620. [Google Scholar] [CrossRef] [PubMed]
[7] Lee, C.H., Hsieh, S.Y., Chang, C.J., et al. (2013) Comparison of Clinical Characteristics of Combined Hepatocellular-Cholangiocarcinoma and Other Primary Liver Cancers. Journal of Gastroenterology and Hepatology, 28, 122-127. [Google Scholar] [CrossRef] [PubMed]
[8] Tao, C.Y., Liu, W.R., Jin, L., et al. (2018) Surgical Treat-ment of Combined Hepatocellular-Cholangiocarcinoma Is as Effective in Elderly Patients as It Is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer, 9, 1106-1112. [Google Scholar] [CrossRef] [PubMed]
[9] Jarnagin, W.R., Weber, S., Tickoo, S.K., et al. (2002) Combined Hepatocel-lular and Cholangiocarcinoma: Demographic, Clinical, and Prognostic Factors. Cancer, 94, 2040-2046. [Google Scholar] [CrossRef] [PubMed]
[10] Aoki, K., Takayasu, K., Kawano, T., et al. (1993) Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Clinical Features and Computed Tomographic Findings. Hepatology, 18, 1090-1095. [Google Scholar] [CrossRef] [PubMed]
[11] Fowler, K.J., Sheybani, A., Parker, R.A., et al. (2013) Combined Hepatocellular and Cholangiocarcinoma (Biphenotypic) Tumors: Imaging Features and Diagnostic Accuracy of Con-trast-Enhanced CT and MRI. American Journal of Roentgenology, 201, 332-339. [Google Scholar] [CrossRef] 
[12] Brunt, E., Aishima, S., Clavien, P.A., et al. (2018) cHCC-CCA: Con-sensus Terminology for Primary Liver Carcinomas with both Hepatocytic and Cholangiocytic Differentation. Hepatology, 68, 113-126. [Google Scholar] [CrossRef] [PubMed]
[13] De Jong, M.C., Nathan, H., Sotiropoulos, G.C., et al. (2011) Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. Journal of Clinical Oncology, 29, 3140-3145. [Google Scholar] [CrossRef] 
[14] Mason, W.S., Gill, U.S., Litwin, S., et al. (2016) HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology, 151, 986-998.e4. [Google Scholar] [CrossRef] [PubMed]
[15] Pollicino, T. and Caminiti, G. (2021) HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13, 368. [Google Scholar] [CrossRef] [PubMed]
[16] Connell, L.C., Harding, J.J., Shia, J., et al. (2016) Combined Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Chinese Clinical Oncology, 5, 66. [Google Scholar] [CrossRef] [PubMed]
[17] Tickoo, S.K., Zee, S.Y., Obiekwe, S., et al. (2002) Combined Hepa-tocellular-Cholangiocarcinoma: A Histopathologic, Immunohistochemical, and in Situ Hybridization Study. The American Journal of Surgical Pathology, 26, 989-997. [Google Scholar] [CrossRef] [PubMed]
[18] Li, R., Yang, D., Tang, C.L., et al. (2016) Combined Hepatocellular Carcinoma and Cholangiocarcinoma (Biphenotypic) Tumors: Clinical Characteristics, Imaging Features of Contrast-Enhanced Ultrasound and Computed Tomography. BMC Cancer, 16, Article No. 158. [Google Scholar] [CrossRef] [PubMed]
[19] Cui, K., Ou, Y., Shen, Y., et al. (2020) Clinical Value of Circu-lating Tumor Cells for the Diagnosis and Prognosis of Hepatocellular Carcinoma (HCC): A Systematic Review and Me-ta-Analysis. Medicine (Baltimore), 99, e22242. [Google Scholar] [CrossRef] 
[20] Trevisan Franca de Lima, L., Broszczak, D., Zhang, X., et al. (2020) The Use of Minimally Invasive Biomarkers for the Diagnosis and Prognosis of Hepatocellular Carcinoma. Bio-chimica et Biophysica Acta—Reviews on Cancer, 1874, Article ID: 188451. [Google Scholar] [CrossRef] [PubMed]
[21] Garancini, M., Goffredo, P., Pagni, F., et al. (2014) Combined Hepatocellular-Cholangiocarcinoma: A Population-Level Analysis of an Uncommon Primary Liver Tumor. Liver Trans-plantation, 20, 952-959. [Google Scholar] [CrossRef] [PubMed]
[22] Agrawal, S. and Belghiti, J. (2011) Oncologic Resection for Malignant Tu-mors of the Liver. Annals of Surgery, 253, 656-665. [Google Scholar] [CrossRef] 
[23] Ma, K.W. and Chok, K.S.H. (2017) Importance of Surgical Margin in the Outcomes of Hepatocholangiocarcinoma. World Journal of Hepatology, 9, 635-641. [Google Scholar] [CrossRef] [PubMed]
[24] Kassahun, W.T. and Hauss, J. (2008) Management of Combined Hepatocellular and Cholangiocarcinoma. International Journal of Clinical Practice, 62, 1271-1278. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, K.H., Lee, S.G., Park, E.H., et al. (2009) Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma. An-nals of Surgical Oncology, 16, 623-629. [Google Scholar] [CrossRef] [PubMed]
[26] Vauthey, J.N., Pawlik, T.M., Abdalla, E.K., et al. (2004) Is Ex-tended Hepatectomy for Hepatobiliary Malignancy Justified? Annals of Surgery, 239, 722-730. [Google Scholar] [CrossRef] [PubMed]
[27] Sasaki, A., Kawano, K., Aramaki, M., et al. (2001) Clinicopathologic Study of Mixed Hepatocellular and Cholangiocellular Carcinoma: Modes of Spreading and Choice of Surgical Treatment by Reference to Macroscopic Type. Journal of Surgical Oncology, 76, 37-46. [Google Scholar] [CrossRef] 
[28] Vilchez, V., Shah, M.B., Daily, M.F., et al. (2016) Long-Term Outcome of Patients Undergoing Liver Transplantation for Mixed Hepatocellular Carcinoma and Cholangiocarcinoma: An Analysis of the UNOS Database. HPB (Oxford), 18, 29-34. [Google Scholar] [CrossRef] [PubMed]
[29] Dageforde, L.A., Vachharajani, N., Tabrizian, P., et al. (2021) Mul-ti-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 232, 361-371. [Google Scholar] [CrossRef] [PubMed]
[30] Zhang, G., Chen, B.W., Yang, X.B., et al. (2022) Prognos-tic Analysis of Patients with Combined Hepatocellular-Cholangiocarcinoma after Radical Resection: A Retrospective Multicenter Cohort Study. World Journal of Gastroenterology, 28, 5968-5981. [Google Scholar] [CrossRef] [PubMed]
[31] Malik, I.A., Rajput, M., Werner, R., et al. (2022) Differential in Vitro Effects of Targeted Therapeutics in Primary Human Liver Cancer: Importance for Combined Liver Cancer. BMC Cancer, 22, Article No. 1193. [Google Scholar] [CrossRef] [PubMed]
[32] Weber, S.M., Ribero, D., O’reilly, E.M., et al. (2015) Intrahe-patic Cholangiocarcinoma: Expert Consensus Statement. HPB (Oxford), 17, 669-680. [Google Scholar] [CrossRef] [PubMed]

为你推荐